We were delighted to catch up with Dr Andrew Blauvelt (Oregon Medical Research Center, Portland, OR, USA) to discuss the interim results for the ECZTEND study (NCT03587805) investigating tralokinumab in patients with atopic dermatitis.
His abstract entitled ‘Long-term improvements observed in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: an ECZTEND interim analysis‘ was presented at AAD VMX, 23-25 April 2021.
- Could you tell us a little about the aims, design and patient population of the ECZTEND study? (0:16)
- What have we learned from the interim efficacy findings of the ECZTEND study? (2:21)
Disclosures: Dr. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Atopic Dermatitis
Kim Papp, AAD VMX 2021: Ruxolitinib Phase 3 Subgroup Analysis
It was a pleasure to speak with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) around the efficacy and tolerability of ruxolitinib cream in the treatment of atopic dermatitis (NCT03745638 & NCT03745651). The abstract ‘Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Clinical Characteristics: Pooled Subgroup Analysis From Two Randomized […]
Amy S. Paller, AAD VMX: Dupilumab LIBERTY AD PEDS Trial
We were delighted to speak with Prof. Amy S. Paller (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) about the results from the phase 3, LIBERTY AD PEDS trial (NCT03345914). This double-blind, 16-week study investigated duplimuab in children with atopic dermatitis. Her abstract entitled ‘Dupilumab Provides Clinically Meaningful Improvement in Atopic Dermatitis (AD) Signs, […]
Amy S. Paller, AAD VMX: Advances in the Treatment of Atopic Dermatitis in Children
Following the AAD VMX meeting we caught up with Prof. Amy S. Paller (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss some of the presentations and recent advances being made in the treatment of children with atopic dermatitis. Disclosures: Prof. Amy Paller has acted as a consultant with honorarium for AbbVie, Abeona, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!